Beili Gao

701 total citations
24 papers, 278 citations indexed

About

Beili Gao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Beili Gao has authored 24 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Beili Gao's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Beili Gao is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Beili Gao collaborates with scholars based in China, Netherlands and Canada. Beili Gao's co-authors include Yi Xiang, Ling Zhou, Jiaan Hu, Zhihong Xu, Ran Zeng, Xue Wu, Junbiao Hang, Yang Shao, Lifeng Luo and Jiani C. Yin and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Beili Gao

24 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beili Gao China 10 135 122 106 42 25 24 278
Sara Fancelli Italy 9 197 1.5× 103 0.8× 134 1.3× 58 1.4× 28 1.1× 25 302
Atsutaka Masuda Japan 9 85 0.6× 142 1.2× 51 0.5× 92 2.2× 25 1.0× 19 279
Yasuyuki Kanke Japan 10 141 1.0× 124 1.0× 78 0.7× 56 1.3× 32 1.3× 24 288
Qianggang Dong China 10 161 1.2× 203 1.7× 57 0.5× 113 2.7× 25 1.0× 24 342
Yuandeng Luo China 8 67 0.5× 184 1.5× 53 0.5× 90 2.1× 25 1.0× 12 285
Hexiao Tang China 9 105 0.8× 178 1.5× 78 0.7× 101 2.4× 16 0.6× 24 326
Αναστασία Κατσιαμπούρα United States 8 139 1.0× 108 0.9× 82 0.8× 114 2.7× 52 2.1× 17 303
Enrico Caliman Italy 9 145 1.1× 60 0.5× 81 0.8× 32 0.8× 27 1.1× 24 219
Joana Assis Portugal 14 100 0.7× 195 1.6× 63 0.6× 122 2.9× 16 0.6× 30 392
Makoto Edagawa Japan 10 87 0.6× 117 1.0× 103 1.0× 42 1.0× 16 0.6× 28 329

Countries citing papers authored by Beili Gao

Since Specialization
Citations

This map shows the geographic impact of Beili Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beili Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beili Gao more than expected).

Fields of papers citing papers by Beili Gao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beili Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beili Gao. The network helps show where Beili Gao may publish in the future.

Co-authorship network of co-authors of Beili Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Beili Gao. A scholar is included among the top collaborators of Beili Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beili Gao. Beili Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Lifeng, Ling Zhou, Ziwei Xu, et al.. (2024). Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities. Cancer Cell International. 24(1). 84–84. 1 indexed citations
2.
Zhou, Ling, Yi Xiang, Zijun Qian, et al.. (2023). The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC. Open Life Sciences. 18(1). 20220533–20220533. 2 indexed citations
3.
Bao, Zhiyao, Lifeng Luo, Tian Xu, et al.. (2022). Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study. Annals of Translational Medicine. 10(18). 967–967. 5 indexed citations
4.
Gao, Beili & Ran Zeng. (2022). Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation. Frontiers in Medicine. 8. 772998–772998. 3 indexed citations
5.
Yang, Jin, Ran Zeng, Jianping Zhou, et al.. (2022). Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Translational Lung Cancer Research. 11(6). 1038–1050. 13 indexed citations
6.
Zeng, Ran, Fang Liu, Jin Yang, et al.. (2021). PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients. Frontiers in Immunology. 12. 724443–724443. 50 indexed citations
7.
8.
Li, Dongsheng, et al.. (2021). An Algorithm for Path Planning of Autonomous Ships Considering the Influence of Wind and Wave. Journal of Physics Conference Series. 2083(3). 32028–32028. 1 indexed citations
9.
Gao, Beili, Fujun Yang, Ming Han, et al.. (2021). Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma. Neoplasia. 23(9). 870–878. 5 indexed citations
10.
Wang, Xiaofei, Ling Zhou, Jiani C. Yin, et al.. (2019). Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy. Journal of Thoracic Oncology. 14(5). e85–e88. 44 indexed citations
11.
Zhang, Jing, et al.. (2018). Monitoring antiangiogenesis of bevacizumab in zebrafish. Drug Design Development and Therapy. Volume 12. 2423–2430. 24 indexed citations
12.
You, Changxuan, Yang Yu, & Beili Gao. (2018). Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity. Cellular Physiology and Biochemistry. 49(1). 235–244. 7 indexed citations
13.
Jian, Hong, Wěi Li, Zhiyong Ma, et al.. (2017). Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports. 7(1). 8483–8483. 6 indexed citations
14.
Sun, Wenwen, Chao‐Fu Wang, Fang Wu, et al.. (2017). Pulmonary enteric adenocarcinoma with pancreatic metastasis: A case report. Oncology Letters. 13(6). 4651–4656. 11 indexed citations
15.
Wang, Xiaofei, Keqiang Chen, Ying Yu, et al.. (2017). Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. Oncotarget. 8(65). 109068–109078. 13 indexed citations
16.
Xu, Zhihong, Caihong Liu, Junbiao Hang, Beili Gao, & Jiaan Hu. (2017). Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM). Cancer Biomarkers. 20(4). 581–588. 5 indexed citations
17.
Chen, Wei, et al.. (2016). Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. Scientific Reports. 6(1). 21359–21359. 30 indexed citations
18.
19.
20.
Ma, Lianchuan & Beili Gao. (2004). Design and Realization of Highly Safe Fault Tolerant Control Computer. Zhongguo anquan kexue xuebao. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Fancelli Breakdown of academic impact, for papers by Atsutaka Masuda Breakdown of academic impact, for papers by Yasuyuki Kanke Breakdown of academic impact, for papers by Qianggang Dong Breakdown of academic impact, for papers by Yuandeng Luo Breakdown of academic impact, for papers by Hexiao Tang Breakdown of academic impact, for papers by Αναστασία Κατσιαμπούρα Breakdown of academic impact, for papers by Enrico Caliman Breakdown of academic impact, for papers by Joana Assis Breakdown of academic impact, for papers by Makoto Edagawa
Rankless by CCL
2026